Report Sections

See All Reports

  • HP:0011505: Cystoid macular edema
  • Pneumonia (382) Neoplasm (47) Respiratory tract infection (46) Diabetes mellitus (39) Abnormality of the cardiovascular system (39) Depressivity (35) Abnormal lung morphology (33) Hypoxemia (30) Acute kidney injury (29) Hypertension (25) Thromboembolism (23) Myocardial infarction (22) Anosmia (21) Mental deterioration (21) Arthritis (20) Type II diabetes mellitus (20) Chronic pulmonary obstruction (19) Leukemia (18) Pulmonary fibrosis (18) Pulmonary obstruction (18) Abnormality of the kidney (17) Stroke (17) Congestive heart failure (16) Abnormality of coagulation (16) Pulmonary embolism (16) Neoplasm of the lung (16) Rheumatoid arthritis (15) Asthma (15) Interstitial pneumonitis (15) Crohn's disease (15) Autistic behavior (14) Chronic pain (14) Type I diabetes mellitus (13) Deep venous thrombosis (12) Ulcerative colitis (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Carcinoma (11) Alzheimer disease (10) Lymphoma (10) Chronic kidney disease (10) Myocarditis (10) Low levels of vitamin D (10) Sepsis (10) Renal insufficiency (9) Dementia (9) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Weight loss (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Behavioral abnormality (8) Psychosis (8) Infertility (8) Abnormality of the gastrointestinal tract (8) Migraine (7) Breast carcinoma (7) Psoriasiform dermatitis (7) Peripheral arterial stenosis (7) Fatigue (7) Schizophrenia (7) Encephalopathy (6) Lymphopenia (6) Dysphagia (6) Bronchiectasis (6) Immunodeficiency (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Obstructive sleep apnea (6) Sleep apnea (6) Prostate cancer (6) Non-small cell lung carcinoma (6) Neoplasm of the large intestine (6) Seizure (5) Premature birth (5) Difficulty walking (5) Gastroparesis (5) Neoplasm of the pancreas (5) Autoimmunity (5) Knee osteoarthritis (5) Disseminated intravascular coagulation (5) Lymphoid leukemia (5) Inflammatory abnormality of the skin (5) Neoplasm of head and neck (5) Allergy (5) Eczema (4) Atopic dermatitis (4) Hepatic fibrosis (4) Cardiac arrest (4) Abnormality of blood and blood-forming tissues (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Headache (4) Colon cancer (4) Reduced factor VIII activity (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Renal cell carcinoma (4) Abnormal anterior horn cell morphology (4) Attention deficit hyperactivity disorder (4) Amyotrophic lateral sclerosis (4) Arrhythmia (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Abnormality of the eye (3) Obsessive-compulsive behavior (3) Abnormality of the endocrine system (3) Spastic diplegia (3) Polyneuropathy (3) Meningitis (3) Hepatic steatosis (3) Abnormal heart morphology (3) Cardiomyopathy (3) Tachycardia (3) Fever (3) Hypothermia (3) Apnea (3) Celiac disease (3) Myelodysplasia (3) Acute myeloid leukemia (3) Myeloproliferative disorder (3) Chronic lymphatic leukemia (3) Multiple myeloma (3) Cystoid macular edema (3) Postprandial hyperglycemia (3) Cutaneous melanoma (3) Small cell lung carcinoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Bulimia (3) Hypogeusia (2) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Periodontitis (2) Agoraphobia (2) Nephrolithiasis (2) Abnormality of the thyroid gland (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Keratoconjunctivitis sicca (2) Spasticity (2) Hemiparesis (2) Abnormal joint morphology (2) Aortic valve stenosis (2) Angina pectoris (2) Pancreatitis (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Male infertility (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Chronic bronchitis (2) Lymphoproliferative disorder (2) Intervertebral disc degeneration (2) Stomatitis (2) Stridor (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) B-cell lymphoma (2) Myeloid leukemia (2) Bronchitis (2) Pain (2) Cervix cancer (2) Cholangitis (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Abnormality of the nervous system (1) Aggressive behavior (1) IgA deposition in the glomerulus (1) Oligospermia (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Syncope (1) Cerebral hemorrhage (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Iron deficiency anemia (1) Anemia (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Hyperkalemia (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Myelomeningocele (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Vascular dilatation (1) Recurrent E. coli infections (1) Osteomyelitis (1) Tachypnea (1) Central apnea (1) Embryonal neoplasm (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Allergic rhinitis (1) Skeletal muscle atrophy (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Enterocolitis (1) Intermittent claudication (1) Thrombophlebitis (1) Supraventricular tachycardia (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Spontaneous abortion (1) Venous insufficiency (1) Monoclonal immunoglobulin M proteinemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Uterine neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) Ciliary dyskinesia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Rhinitis (1) Seasonal allergy (1) Hypercapnia (1) Restless legs (1) Non-Hodgkin lymphoma (1) Membranous nephropathy (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Ductal carcinoma in situ (1) Heart murmur (1) Cardiogenic shock (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Brain neoplasm (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Sarcoma (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Rectal fistula (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Halitosis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0011505: Cystoid macular edema

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (9)


    Name (Synonyms) Correlation
    drug1240 Dabigatran etexilate + BI 1323495 Wiki 0.58
    drug1239 Dabigatran etexilate Wiki 0.58
    drug1434 EXN407 Wiki 0.58
    Name (Synonyms) Correlation
    drug1266 Data collection up to 1 year Wiki 0.58
    drug5024 life questionnaires Wiki 0.58
    drug3728 Rosuvastatin + BI 1323495 Wiki 0.58
    drug3724 Rosuvastatin Wiki 0.29
    drug5169 questionnaire Wiki 0.19
    drug3495 Questionnaire Wiki 0.10

    Correlated MeSH Terms (7)


    Name (Synonyms) Correlation
    D008269 Macular Edema NIH 1.00
    D012170 Retinal Vein Occlusion NIH 0.58
    D011111 Polymyalgia Rheumatica NIH 0.33
    Name (Synonyms) Correlation
    D013700 Giant Cell Arteritis NIH 0.33
    D008268 Macular Degeneration NIH 0.29
    D002908 Chronic Disease NIH 0.15
    D009103 Multiple Sclerosis NIH 0.13

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0012636 Retinal vein occlusion HPO 0.58

    Clinical Trials

    Navigate: Correlations   HPO

    There are 3 clinical trials


    1 COVID-19 Related Lockdown Effects On Chronic Diseases

    The containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.

    NCT04390126
    Conditions
    1. Chronic Coronary Syndrome
    2. Heart Failure
    3. AMD and Macular Edema
    4. Chronic Respiratory Failure
    5. Hemophilia
    6. Malignant Hemopathy
    7. Multiple Sclerosis
    8. Horton's Disease
    Interventions
    1. Other: life questionnaires
    2. Other: questionnaire
    MeSH:Polymyalgia Rheumatica Respiratory Insufficiency Multiple Sclerosis Giant Cell Arteritis Macular Edema Chronic Disease
    HPO:Cystoid macular edema Macular edema

    Primary Outcomes

    Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)

    Measure: % adherence to each pharmacological class

    Time: during the period from 20 April 2020 to 7 May 2020

    Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)

    Measure: number of occurrence of medical events at 1 year

    Time: throughout the study for 12 months

    Secondary Outcomes

    Description: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change

    Measure: Expressed in %: Non-pharmacological treatment/lifestyle:

    Time: during the period from 20 April 2020 to 7 May 2020

    Measure: Expressed in %: Difficulties accessing care: medical appointments, prescriptions, medication

    Time: during the period from 20 April 2020 to 7 May 2020

    Measure: Measurement of psychological distress: Kessler's specific questionnaire (score between 0 and 24)

    Time: during the period from 20 April 2020 to 7 May 2020
    2 Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents

    In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.

    NCT04395859
    Conditions
    1. Age Related Macular Degeneration
    2. Diabetic Macular Edema
    3. Retinal Vein Occlusion
    Interventions
    1. Procedure: Questionnaire
    2. Other: Data collection up to 1 year
    MeSH:Macular Degener Macular Degeneration Macular Edema Retinal Vein Occlusion
    HPO:Cystoid macular edema Macular edema Retinal vein occlusion

    Primary Outcomes

    Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up

    Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic

    Time: Baseline (Before confinement) and 6 months after resumption of follow-up
    3 A Randomised, Double-Masked Vehicle-Controlled, Multiple Dose, Dose Escalation Study To Evaluate The Safety and Tolerability of EXN407 in Subjects With Centre Involved Diabetic Macular Oedema Secondary to Diabetes Mellitus

    This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with Centre-subfield macular thickness (CMT) between 280-420 µm and Best corrected visual acuity (BCVA) better than approximate Snellen equivalent 20/32 (6/9, 78 letters) in the study eye, which is considered secondary to diabetes mellitus. For brevity, the BCVA criteria will be noted as 20/32 (6/9). This study will provide a basis for further clinical development of EXN407 ophthalmic solution.

    NCT04565756
    Conditions
    1. Diabetic Macular Edema
    Interventions
    1. Drug: EXN407
    MeSH:Macular Edema
    HPO:Cystoid macular edema Macular edema

    Primary Outcomes

    Description: Measured by frequency and severity of ocular AEs in the study and contralateral eyes.

    Measure: The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Escalation phase.

    Time: Assessed starting from Day 1 of treatment to Day 36 in Dose Escalation.

    Description: Measured by frequency and severity of ocular AEs in the study and contralateral eyes.

    Measure: The primary objective of the study is to evaluate the ocular safety and tolerability (by incidence of ocular adverse events) of EXN407 ophthalmic solution in Dose Expansion phase.

    Time: Assessed starting from Day 1 of treatment to Day 113 in Dose Expansion phase.

    Secondary Outcomes

    Description: Measured by characterizing the PK profile by estimating the time of the maximum plasma drug concentration (Tmax) of EXN407 in plasma.

    Measure: To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by Tmax.

    Time: Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.

    Description: Measured by characterizing the PK profile by estimating the maximum observed drug plasma concentration (Cmax) of EXN407 in plasma.

    Measure: To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by Cmax

    Time: Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.

    Description: Measured by characterizing the PK profile by estimating the area under the curve (AUC) of EXN407 in plasma.

    Measure: To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by AUC.

    Time: Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.

    Description: Measured by characterizing the PK profile by estimating the apparent elimination half-life (t½) of EXN407 in plasma.

    Measure: To evaluate the systemic pharmacokinetics of EXN407 ophthalmic solution in subjects with DMO secondary to diabetes mellitus by t½.

    Time: Blood draws for PK will be collected only on Day 3(Dose Escalation) and Day 8(Dose Expansion) at the following timepoints: pre-dose and 15 mins, 30 mins, 1, 2, 3,and 4 hours post-dose.

    Description: Measured by the changes from baseline in ophthalmic examination finding through ophthalmoscopy.

    Measure: To evaluate the percentage (%) of changes in ocular functional measures as assessed using ophthalmoscopy.

    Time: From Day 1 of Treatment to End of Treatment i.e. assessed upto 36 Days in Dose Escalation and upto 4 months(113 days) in Dose Expansion.

    Description: Measured by the changes from baseline in ophthalmic examination finding through ophthalmoscopy.

    Measure: To evaluate the percentage (%) of changes in ocular structural measures as assessed using ophthalmoscopy.

    Time: From Day 1 of Treatment to End of Treatment i.e. assessed upto 36 Days in Dose Escalation and upto 4 months(113 days) in Dose Expansion.

    HPO Nodes


    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook